Fig. 1From: Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II studyTrial flow diagram. AHCC, active hexose correlated compound; BR, borderline resectable; ECOG-PS, Eastern Cooperative Oncology Group performance status; NAT, neoadjuvant therapy; PDAC, pancreatic ductal adenocarcinoma; R, resectableBack to article page